Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Dose-Escalation in Knee Osteoarthritis
NCT02139319Phase 1Completed
- Sponsor
- Galderma
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing Botulinum toxin with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events at 6 weeks. Started Mar 2014; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02139319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02139319.